Development of precise diagnostic tools is crucial in combating Nipah virus infection. Leveraging our expertise in IVD reagents and equipment, our company stands at the forefront of Nipah virus infection diagnosis development, dedicated to enhancing disease surveillance and safeguarding public health.
Introduction to Nipah Virus Infection
The Nipah virus (NiV) is a zoonotic pathogen that primarily circulates in countries such as Bangladesh and India. This virus is transmitted from animals to humans, with fruit bats being the primary hosts. Modes of transmission include contact with infected animal fluids, consumption of contaminated food, and close human-to-human contact. Infection with the virus can lead to a range of symptoms, from mild flu-like symptoms to severe encephalitis and respiratory distress, and can trigger neurological complications.
Fig. 1 Schematic diagram of Nipah virus replication. (Banerjee, et al., 2019)
Diagnostic Biomarkers for Nipah Virus Infection
Diagnostic biomars play a vital role in early testing, monitoring and management of Nipah virus infection. These biomarkers are measured indicators that reflect the existence or progress of individual diseases.
Nucleocapsid Protein
The Nucleocapsid protein of the Nipah virus serves a crucial function in viral replication. Increased levels of this protein signify viral activity, rendering it a valuable indicator for the early detection of Nipah virus infection.
Viral RNA
Quantifying the viral RNA load in samples such as blood or respiratory secretions directly indicates the replication status of the Nipah virus. PCR testing can accurately measure the levels of viral RNA, aiding in the early diagnosis of the disease.
Antibodies
Detection of Nipah virus-specific antibodies (including IgM and IgG) in serum samples indicates recent or past infection. Serological tests measuring antibody titers provide valuable information about the immune response to the virus.
IVD Development for Nipah Virus Infection
The symptoms of Nipah virus infection closely resemble those of common illnesses, potentially leading to misdiagnosis or delayed diagnosis. Creating in vitro diagnostic (IVD) kits for Nipah virus infection is crucial for prompt detection, epidemic control, and efficient disease management. The development of the IVD kit for the Nippa virus infection is mainly based on several aspects:
| Kits |
Applications |
Detection Methods |
| Nipah Virus RNA Detection Kit |
Detection of the virus RNA in the sample. |
RT-PCR, Nucleic Acid Hybridization |
| IgM and IgG Antibody Detection Kit |
Qualitative testing of Nipah virus specific antibodies (IgM and IgG) in serum. |
ELISA |
| Nucleocapsid Protein Detection Kit |
Identification of Nipah virus nucleocapsid protein. |
Immunochromatography |
| Point-of-care Testing (POCT) Kit |
Fast detection of Nipah virus antigen. |
Lateral Flow Assays |
Our Services
Acknowledging the challenges associated with diagnosing rare infectious diseases like Nipah virus infection, our company is dedicated to creating cutting-edge IVD solutions to address unmet needs in this area. Our specialized focus lies in designing RNA, antigen, and antibody detection kits for Nipah virus infection. In order to bolster diagnostic capabilities in resource-constrained settings, we are dedicated to developing point-of-care testing (POCT) products to promote the rapid identification and effective control of Nipah virus infection.
Companion diagnostics are essential parts of personalized healthcare, aiding in formulating therapeutic decisions tailored to affected individuals. Our companion diagnostic development service is focused on creating diagnostic tests to supplement the therapeutic strategy for Nipah virus infection and optimize therapeutic outcomes.
If you are interested in our services, please don't hesitate to reach out to us for further information and pricing details on the services we offer.
Reference
- Jensen, Kenneth S., et al. "Development of a novel real-time polymerase chain reaction assay for the quantitative detection of Nipah virus replicative viral RNA." PLoS One 13.6 (2018): e0199534.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
